GLP-1 RA – Moving the Needle for Injectable Therapies for Adult Patients With T2D
Industry Webcast Sponsored by Novo Nordisk; Not for CME/CE Credit
March 18, 2021 | 12:25 PM - 1:10 PM ET
Evaluate when the guidelines recommend GLP-1 RA use for T2D treatment. Review the glucose-dependent mechanism of action, safety, and dosing of a once-weekly GLP-1 RA. Discuss the efficacy and safety data from pivotal T2D glycemic control trials and from the cardiovascular outcomes trial.
This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.
North Texas Diabetes Center in Plano (Texas)
Clinical Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism
University of Texas Southwestern Medical Center at Dallas